We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00524615
Recruitment Status : Unknown
Verified June 2012 by Jan Vaclavík, University Hospital Olomouc.
Recruitment status was:  Recruiting
First Posted : September 3, 2007
Last Update Posted : June 20, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to evaluate the efficacy of spironolactone on lowering blood pressure when added to therapy in patients with resistant arterial hypertension.

Condition or disease Intervention/treatment Phase
Hypertension Drug: spironolactone Phase 4

Detailed Description:

Arterial hypertension resistant to therapy and requiring treatment with more then three antihypertensive drugs is common. At present there are is no standard therapy for resistant hypertension based on randomised clinical trials, neither data to guide addition of further drugs to therapy. Recently some observational and retrospective trials reported good effect of spironolactone in patients with resistant hypertension, but these data were not validated by prospective randomised clinical trials.

This is a multicentric, randomised, double blind clinical trial, which will evaluate the effect of addition of 25 mg spironolactone to current medication compared to placebo. The study will enroll patients with blood pressure over 140/90 mmHg during a clinical examination, which are using at least three antihypertensive drugs, one of them being a diuretic. Average daytime systolic and diastolic blodd pressure will be evaluated by ABPM (ambulatory blood pressure monitoring).

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Addition of Spironolactone in Patients With Resistant Arterial Hypertension
Study Start Date : September 2007
Estimated Primary Completion Date : October 2012
Estimated Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: 1
25 mg of Spironolactone oraly once daily
Drug: spironolactone
25 mg of spironolactone once daily or placebo for 2 months
Placebo Comparator: 2
placebo oraly once daily
Drug: spironolactone
25 mg of spironolactone once daily or placebo for 2 months

Outcome Measures

Primary Outcome Measures :
  1. Average daytime systolic and diastolic blodd pressure evaluated by ABPM (ambulatory blood pressure monitoring) [ Time Frame: before and after 2 months of treatment ]

Secondary Outcome Measures :
  1. changes of serum potassium, natrium, creatinine, body weight, casual blood pressure in office, treatment response for different baseline levels of aldosterone and aldosterone/PRA ratio [ Time Frame: 2 months of follow-up ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients over 18 years
  • Resistant arterial hypertension: (blood pressure during clinical control exceeding 140/90 mmHg (or 130/80 mmHg in in diabetic patients or patients with renal disease with creatinine level of more than 133 μmol per liter or urinary protein excretion of more than 300 mg over a 24-hour period) despite adherence to treatment with full doses of at least three antihypertensive medications, including a diuretic

Exclusion Criteria:

  • Pregnant or breastfeeding women, women in fertile age without ruled out pregnancy
  • Severe hypertension over 180/110 mmHg
  • Renal insufficiency with creatinine over 180 umol/l or GFR lower than 40 ml/min
  • Hyperkalemia over 5,4 mmol/l, hyponatremia below 130 mmol/l
  • Porphyria
  • Hypersensitivity to the compounds of Verospiron (Richter Gedeon, Hungary) drug
  • Patients taking any aldosterone antagonist (spironolactone, eplerenone, kanreone)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524615

Contact: Jan Václavík, MD. +420588443209 vaclavk.j@centrum.cz

Czech Republic
Olomouc University Hospital and Palacký University School of Medicine Recruiting
Olomouc, Czech Republic, 775 20
Contact: Jan Václavík, MD.         
Principal Investigator: Jan Václavík, MD.         
Sponsors and Collaborators
Jan Vaclavík
Czech Society of Hypertension
Prostejov Hospital
Brno University Hospital
Olomouc Military Hospital
Gedeon Richter Ltd.
Study Director: Jan Václavík, MD. Internal medicine department I, Olomouc university hospital and Palacký University School of medicine
Principal Investigator: Bořek Lačňák, MD. Internal Medicine Dept., Šternberk Hospital
Principal Investigator: Martin Plachý, MD. Internal medicine department II, Brno University Hospital
More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jan Vaclavík, Principal investigator, University Hospital Olomouc
ClinicalTrials.gov Identifier: NCT00524615     History of Changes
Other Study ID Numbers: ASPIRANT-1
EudraCT 2007-003558-27
First Posted: September 3, 2007    Key Record Dates
Last Update Posted: June 20, 2012
Last Verified: June 2012

Keywords provided by Jan Vaclavík, University Hospital Olomouc:
resistant hypertension treatment
aldosterone antagonists
resistant arterial hypertension
refractory arterial hypertension

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents